image
Healthcare - Biotechnology - NASDAQ - IE
$ 27.295
0 %
$ 4.5 B
Market Cap
12.27
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ALKS stock under the worst case scenario is HIDDEN Compared to the current market price of 27.3 USD, Alkermes plc is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ALKS stock under the base case scenario is HIDDEN Compared to the current market price of 27.3 USD, Alkermes plc is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ALKS stock under the best case scenario is HIDDEN Compared to the current market price of 27.3 USD, Alkermes plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALKS

image
$36.0$36.0$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.0$24.0$24.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
1.56 B REVENUE
-6.36%
421 M OPERATING INCOME
1.57%
367 M NET INCOME
3.18%
439 M OPERATING CASH FLOW
9.41%
-111 M INVESTING CASH FLOW
-208.61%
-494 M FINANCING CASH FLOW
-70.56%
430 M REVENUE
13.71%
163 M OPERATING INCOME
55.30%
147 M NET INCOME
58.59%
190 M OPERATING CASH FLOW
133.36%
-13.9 M INVESTING CASH FLOW
87.31%
-282 M FINANCING CASH FLOW
-153.50%
Balance Sheet Alkermes plc
image
Current Assets 1.42 B
Cash & Short-Term Investments 752 M
Receivables 385 M
Other Current Assets 279 M
Non-Current Assets 640 M
Long-Term Investments 73.1 M
PP&E 312 M
Other Non-Current Assets 255 M
36.57 %18.71 %13.58 %3.56 %15.17 %12.42 %Total Assets$2.1b
Current Liabilities 465 M
Accounts Payable 45.6 M
Short-Term Debt 6.17 M
Other Current Liabilities 413 M
Non-Current Liabilities 125 M
Long-Term Debt 69.4 M
Other Non-Current Liabilities 56 M
7.73 %70.00 %11.75 %9.49 %Total Liabilities$590.6m
EFFICIENCY
Earnings Waterfall Alkermes plc
image
Revenue 1.56 B
Cost Of Revenue 245 M
Gross Profit 1.31 B
Operating Expenses 892 M
Operating Income 421 M
Other Expenses 53.6 M
Net Income 367 M
2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m002b(245m)1b(892m)421m(54m)367mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
84.25% GROSS MARGIN
84.25%
27.00% OPERATING MARGIN
27.00%
23.57% NET MARGIN
23.57%
25.06% ROE
25.06%
17.86% ROA
17.86%
22.09% ROIC
22.09%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alkermes plc
image
500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 367 M
Depreciation & Amortization 28.5 M
Capital Expenditures -33.5 M
Stock-Based Compensation 96.6 M
Change in Working Capital -98.2 M
Others 13.3 M
Free Cash Flow 406 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alkermes plc
image
Wall Street analysts predict an average 1-year price target for ALKS of $35 , with forecasts ranging from a low of $25 to a high of $40 .
ALKS Lowest Price Target Wall Street Target
25 USD -8.41%
ALKS Average Price Target Wall Street Target
35 USD 28.23%
ALKS Highest Price Target Wall Street Target
40 USD 46.55%
Price
Max Price Target
Min Price Target
Average Price Target
4040383836363434323230302828262624242222Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Alkermes plc
image
Sold
0-3 MONTHS
12.1 M USD 2
3-6 MONTHS
8.25 M USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Alkermes to Report First Quarter Financial Results on May 1, 2025 DUBLIN , April 17, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. prnewswire.com - 2 weeks ago
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference DUBLIN , April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. prnewswire.com - 1 month ago
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia. zacks.com - 1 month ago
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia DUBLIN , April 1, 2025 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and IH – chronic, neurological disorders characterized by excessive daytime sleepiness. prnewswire.com - 1 month ago
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder – Survey Respondents Reported That Medication Adherence is a Top Concern for Healthcare Providers When Selecting Treatments and Frequent Medication Switches Can Have Significant Impacts on Patients' Experiences and Quality of Life – – 98% of Respondents Agreed* That Quality of Life for a Patient is Just as Important as Symptom Management When Thinking About Treatment Effect – DUBLIN , March 27, 2025 /PRNewswire/ -- People living with schizophrenia or bipolar I disorder (BDI) often face long and complex diagnostic and treatment journeys. Results from a newly completed survey designed to better understand the perspectives of healthcare providers on patients' treatment experiences and outcomes indicated that providers often prioritize approaches that support long-term symptom control, treatment consistency and quality of life considerations. prnewswire.com - 1 month ago
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe. zacks.com - 1 month ago
GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait GE Aerospace has formed a flat base, one of several stocks with strong relative strength near buy points and with relatively low volatility. The post GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait appeared first on Investor's Business Daily. investors.com - 1 month ago
Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 month ago
Alkermes to Participate in Upcoming Investor Conferences DUBLIN , Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen 45th Annual Health Care Conference Date/Time: Wednesday, March 5, 2025 at 9:50 a.m. prnewswire.com - 2 months ago
Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment seekingalpha.com - 2 months ago
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year. zacks.com - 2 months ago
Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript Alkermes plc (NASDAQ:ALKS ) Q4 2024 Earnings Conference Call February 12, 2025 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Blair Jackson - Executive Vice President and Chief Operating Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald Umer Raffat - Evercore ISI Jessica Fye - JPMorgan Chris Shibutani - Goldman Sachs Marc Goodman - Leerink Partners Uy Ear - Mizuho Securities Troy Langford - TD Cowen Douglas Tsao - H.C. Wainwright Joel Beatty - Baird Operator Greetings, and welcome to the Alkermes Fourth Quarter 2024 Financial Results Conference Call. seekingalpha.com - 2 months ago
8. Profile Summary

Alkermes plc ALKS

image
COUNTRY IE
INDUSTRY Biotechnology
MARKET CAP $ 4.5 B
Dividend Yield 0.00%
Description Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Contact Connaught House, Dublin, 4 https://www.alkermes.com
IPO Date July 16, 1991
Employees 1800
Officers Mr. Blair C. Jackson Interim Principal Financial Officer, Executive Vice President, Chief Risk Officer & Chief Operating Officer Mr. Stephen Schiavo Senior Vice President & Chief Human Resources Officer Mr. Richard F. Pops Chairman & Chief Executive Officer Mr. C. Todd Nichols Senior Vice President & Chief Commercial Officer Dr. Craig C. Hopkinson M.D. Executive Vice President of Research & Development and Chief Medical Officer Mr. Samuel J. Parisi Interim Principal Accounting Officer & Vice President of Finance Mr. Thomas Harvey Chief Information Officer & Senior Vice President of IT Ms. Sandra Coombs Senior Vice President of Corporate Affairs & Investor Relations Mr. Peter Norman Senior Vice President of Policy & Government Relations Mr. David Joseph Gaffin J.D. Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary